DEDHAM, Mass., April 19 /PRNewswire/ -- Signet Laboratories, Inc. today
announced the availability of two important new affinity purified polyclonal
antibodies used for the identification and measurement of the 40 and 42 amino
acid isoforms of Beta Amyloid. Cerebrovascular deposition of Beta Amyloid
protein is a common pathologic event in Alzheimer's disease and certain
related neurodegenerative disorders. Signet's 40 and 42 specific antibodies
represent the most effective way to determine levels of Beta Amyloid 1-40 and
1-42 protein isoforms in cerebrospinal fluid, plasma, and brain tissue.
Alzheimer's is a disease that presently affects over four million people,
a number that is expected to quadruple over the next fifteen years. There is
no known cure and diagnosis can only be confirmed post mortem. "We are
excited to offer new, quality products in an area with a significant need for
effective and reliable diagnostic chemistries," said Brent Dorval, PhD and
Chief Technical Officer of Signet.
"These antibodies are a direct result of the Company's continued,
aggressive neurodegenerative disease product development program."
Signet Laboratories Inc. (Dedham, MA) is a privately held, leading medical
diagnostics/research company engaged in the development, manufacture and
distribution of monoclonal antibodies and diagnostic assays for cancer,
infectious disease, and neurodegenerative disease. Founded in 1989, Signet is
a commercial spinout of Johnson & Johnson's Cambridge Research Laboratories,
Inc. (CRL, Cambridge, MA).
Contact Information:
Ms. Terri Daly
Marketing Communications
Signet Laboratories, Inc.
180 Rustcraft Road
Dedham, MA 02026
Phone: 781.329.7919, ext. 2017
Fax: 781.461.2456
tdaly@signetlabs.com
SOURCE Signet Laboratories, Inc.
 back to top
Related links:
http://www.signetlabs.com
CONTACT:
Ms. Terri Daly, Marketing Communications of
Signet Laboratories, Inc., +1- 781-329-7919, ext. 2017,
tdaly@signetlabs.com
|
